Abstract
Squamous cell carcinoma, a subtype of non-small cell lung cancer (NSCLC), is strongly associated with smoking, and the prognosis for patients with this disease is dire. Traditional chemotherapeutic approaches are not very effective, and although exciting molecular targets, such as mutated epidermal growth factor receptor (EGFR) and EML4–ALK fusion proteins have been identified in NSCLC, they occur mostly in non-smokers with NSCLC of the adenocarcinoma subtype. Now, reporting in Science Translational Medicine, Jonathan Weiss and colleagues show that fibroblast growth factor receptor 1 (FGFR1) is a promising new molecular target for the treatment of smoking-associated lung cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
